Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Best Practice

Implementing strong access strategies across different country income classifications

Establishing equitable pricing strategies is only one part of the equation in product delivery. Strategies need to be more comprehensive, both for companies and patients, to ensure maximum reach across the income pyramid.

Date

15 November 2022

Ms. Jho-Ann Pulgo sits outside her home
Ms. Jho-Ann Pulgo, who was diagnosed with non-Hodgkin’s lymphoma in 2020, has received treatment – including specifically brentuximab vedotin (Adcetris®) – through the Takeda patient assistance programme. (Credit: Takeda)
Companies
GSK, Pfizer, Takeda
Location
Colombia, India, Uganda (GSK), Mexico, India, Uganda (Pfizer), Philippines, Rwanda, Thailand (Takeda)
Focus
Products indicated for cancer and HIV/AIDS
Action
Applying access strategies that consider ability to pay across upper-middle, lower-middle and low-income countries
Aim
To reach additional patients across the income pyramid and in differing economies

GSK, Pfizer and Takeda demonstrate best practice by addressing accessibility and affordability in their access strategies, showing evidence of tailoring their access strategies to meet the needs of countries in different income brackets.

GSK (via its majority-owned business specialising in HIV products, ViiV Healthcare), demonstrates a comprehensive approach to expanding access to its HIV product abacavir, dolutegravir and lamivudine (ALD) (Triumeq®). Its access strategies include tailored equitable pricing strategies, voluntary licensing accompanied by technology transfers, and health systems strengthening initiatives.

In Colombia (an upper-middle income country) and India (a lower-middle income country), ViiV Healthcare commits to applying a flexible pricing approach that factors in gross national income and public health need. Prices are then refined based on local affordability, domestic healthcare system funding, purchasing patterns and volumes, and accessibility for those living with HIV/AIDS. In Uganda (a low-income country), ViiV Healthcare provides extensive support for health system strengthening activities through its Positive Action programme. ViiV Healthcare uses voluntary licences, enabling generic medicine manufacturers to develop, manufacture and market dolutegravir and dolutegravir-based fixed dose combinations, including ALD. For example, ViiV Healthcare does not currently supply abacavir, dolutegravir and lamivudine (ALD) in India, but partners with two India-based generic medicine manufacturers (Mylan Laboratories Ltd and Aurobindo Pharma) that hold voluntary licences to expedite development of more affordable paediatric dispersible formulations of ALD.

Pfizer uses high-quality access strategies to expand access to palbociclib (Ibrance®), used to treat breast cancer. In Mexico (an upper-middle income country), compared to the previous Index, Pfizer has increased patient reach by continuing with strategies including tiered discounts in the private market, based on co-payment. In India (a lower-middle income country), in 2021 Pfizer introduced a differential approach in a new patient assistance programme, using questionnaires and independent evaluation to assess affordability. In Uganda (a low-income country), its compassionate use programme allows it to make the product available to patients before the product has entered the market.

Takeda was recognised in the 2021 Index for its access strategy for its non-Hodgkin's lymphoma treatment brentuximab vedotin (Adcetris®) in Thailand (an upper-middle income country). Takeda provides evidence of growth in patient reach and uses a third-party organisation to provide data that enables it to tailor prices for individual patients. In the Philippines (a lower-middle income country), where it maintains a patient assistance programme (PAP), it also works with the government to secure funding for medicines and support for diagnostic testing. In addition, it has collaborated with the Philippine Cancer Society to provide financial aid to patients. In Rwanda (a low-income country), once the product is registered, it plans to use inter-country pricing, a PAP and a third-party organisation for evaluative data. Here, it demonstrates best practice by providing patient forecasts to help anticipate demand for the product.

Next steps

The best comprehensive access strategies reflect the needs of a particular country for a specific product. Differentiation is key to increasing affordability, and companies should seek to understand all barriers to access and in each case allow tailoring for affordability. GSK stands out in this area. Pfizer and Takeda deserve credit for increasing patient reach since the last Index. Other companies have yet to follow suit, and all three that lead still have room to improve. All companies should look to apply comprehensive high-quality strategies with consistency, increasing patient reach and widening both their geographic and product scope.

James Hazel

Research Programme Manager

jhazel@accesstomedicinefoundation.org

Get in touch

Resource Center

Read the findings from 2022 Access to Medicine Index
Key findings

First voluntary licence for a cancer treatment is a promising sign for future expansion of access to innovative medicines

15 November 2022
Key findings

More access plans and strategies to expand access to more products, but with limited breadth and depth

15 November 2022

The Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved